Webinar
Highlights from ESMO 2024: How does it affect drug development going forward
October 2, 2024 12:00 PM - 1:00 PM
Join us for an insightful webinar where our expert oncologists and regulatory leaders will delve into key highlights from the recent European Society for Medical Oncology (ESMO) Congress. This session will explore groundbreaking research, innovative treatment approaches, and pivotal clinical trial results presented at ESMO.
Our speakers will analyze whow these developments may influence the strategies of other drug developers, potentially reshaping the landscape of oncology research and treatment. Attendees will gain valuable insights into emerging trends, potential shifts in standard of care, and new opportunities for drug development across vaious cancer types. Don't miss this opportunity to stay ahead of the curve in the rapidly evolving filed of oncology.
Gwyn Bebb, M.D., BM, BCh, Ph.D.
Franchise Head, Oncology
Gwyn Bebb is a Senior Vice President and Global Therapeutic Franchise Head - Oncology at Parexel. Before joining Parexel, he spent two years at Amgen in global drug development. He has 20 years of experience in academic clinical research as a Professor of Medicine and Oncology at the University of Calgary. Gwyn Bebb has experience in trial design, biomarker analysis, drug development, and real-world evidence. He has a medical degree from the University of Oxford, a Doctor of Philosophy in Molecular Pathology from the University of British Columbia, and an undergraduate degree in Natural Sciences from the University of Cambridge.
Sinan Sarac, M.D., Ph.D., M.Sc.
Senior Vice President, Head of Oncology Europe, Regulatory Consulting
Sinan Sarac is Senior Vice President and Head of Regulatory Strategy for Europe at Parexel. Before joining Parexel, he held significant roles at the European Medicines Agency (EMA, including serving on the Committee for Medicinal Products for Human Use (CHMP), the Committee for Advanced Therapies (CAT), and the Scientific Advice Working Party (SAWP). Sinan Sarac also chaired CHMP’s Oncology Working Party (ONCWP). With over a decade of experience within the regulatory system, including regular interactions with the FDA, Health Canada, Swiss Medic, PMDA, and other health/medicines authorities and agencies, Sinan is a distinguished expert in the pharmaceutical and regulatory field.